Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.58
- Piotroski Score 3.00
- Grade Buy
- Symbol (EOLS)
- Company Evolus, Inc.
- Price $17.48
- Changes Percentage (6.19%)
- Change $1.02
- Day Low $16.57
- Day High $17.59
- Year High $17.59
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $22.50
- High Stock Price Target $25.00
- Low Stock Price Target $20.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.04
- Trailing P/E Ratio -11.24
- Forward P/E Ratio -11.24
- P/E Growth -11.24
- Net Income $-61,685,000
Income Statement
Quarterly
Annual
Latest News of EOLS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)
Evolus, Inc. is a performance beauty company focusing on the cash-pay aesthetic market. Analysts project breakeven in 2026 with a 66% annual growth rate. However, the company's high debt-to-equity rat...
By Yahoo! Finance | 2 months ago
